# Follistatin-344 Dosage Protocol Guide: Reconstitution & Administration for Research (2026)
> Research Use Only (RUO): Follistatin-344 is not approved for human use by the FDA, EMA, or any regulatory authority. All protocols described below are derived from published preclinical animal studies and are intended solely for laboratory researchers working under appropriate institutional oversight. This article is for educational and scientific reference only.
Follistatin-344 (FS-344) is among the most powerful myostatin inhibitors available for preclinical research — but it is also one of the most handling-sensitive research proteins in common use. Unlike small synthetic peptides, FS-344 is a full-length glycoprotein that requires careful reconstitution, cold-chain storage, and precise dosing to preserve its biological activity. This guide compiles protocols from published literature to support researchers working with recombinant FS-344 in muscle biology, sarcopenia, and muscle wasting disease models.
For background on follistatin's mechanism of action, isoform biology, and multi-tissue research applications, see our companion Follistatin-344 research profile.
---
What Is Follistatin-344? (Protocol Context)
Follistatin-344 is a 35–38 kDa recombinant glycoprotein that functions as a dual-antagonist of myostatin (GDF-8) and activin A — the two principal negative regulators of skeletal muscle mass that signal through the ActRIIB receptor. When researchers refer to "Follistatin-344" as a research compound, they are working with either:
- •Full-length FS-344 recombinant protein (the full 344-amino-acid precursor form), or
- •Processed FS-315 (the predominant circulating isoform generated from FS-344 after post-translational processing)
Both are available commercially as lyophilized powders from research reagent suppliers. The "344" designation distinguishes this isoform from FS-288 (processed from FS-317) — a distinction that matters critically for administration route and off-target signaling, discussed below.
---
FS-344 vs. FS-315 vs. FS-288: Protocol Implications
Understanding which follistatin isoform you are working with directly affects reconstitution choice, expected pharmacokinetics, and experimental interpretation.
| Isoform | Gene Precursor | MW | HSPG Binding | Primary Distribution | Protocol Implication |
|---|---|---|---|---|---|
| FS-315 (from FS-344) | FST exon 5–6 inclusion | ~35 kDa | Low | Systemic / skeletal muscle preferential | Preferred for systemic SC/IM dosing in muscle models |
| FS-288 (from FS-317) | FST exon 5–6 skip | ~32 kDa | High | Tissue-bound; pituitary, ovarian | Not preferred for systemic muscle research (FSH disruption risk) |
Key distinction for researchers: FS-315's lower affinity for heparan sulfate proteoglycans (HSPGs) on cell surfaces means it distributes more freely in circulation rather than being sequestered at injection-site tissues. This is why gene therapy programs selected the FS-344 cassette (which encodes FS-315) rather than FS-317 — to achieve systemic muscle distribution while minimizing pituitary activin suppression.
When sourcing recombinant protein, confirm the vendor's sequence: if the product is labeled "Follistatin-344" but contains the shorter FS-288 sequence, the pharmacology will differ substantially from FS-344/FS-315 studies in the published literature.
---
Reconstitution Protocol
Follistatin-344 is supplied as a lyophilized (freeze-dried) powder, typically in vials of 100 mcg or 1 mg. Because it is a large glycoprotein rather than a short synthetic peptide, reconstitution requires more care than standard research peptides.
⚠️ Protein Fragility Notes (Critical)
- •Vortexing will denature FS-344. Never vortex. Roll or gently swirl to dissolve.
- •Repeated freeze-thaw cycles degrade activity. Reconstituted solutions should be aliquoted into single-use volumes before first freeze.
- •Foam = denaturation. If foaming occurs during reconstitution, the protein has been compromised.
- •Adsorption loss: FS-344 can adsorb to plain polypropylene tube walls at low concentrations. Use BSA-blocked tubes or add carrier BSA to the reconstitution buffer.
Step-by-Step Reconstitution
Materials:
- •Sterile bacteriostatic water (BAC water) or PBS + 0.1% BSA (bovine serum albumin)
- •Sterile syringes and needles
- •Alcohol swabs
- •Ice / 4°C storage
Protocol:
1. Allow the lyophilized vial to equilibrate to room temperature (approximately 15–20 minutes). Do not rush this step — condensation inside a cold vial can trap powder on the cap.
2. Wipe the vial septum with a 70% isopropyl alcohol swab and allow to dry.
3. Draw the appropriate volume of reconstitution buffer into a sterile syringe.
4. Insert the needle at the vial's shoulder (not directly through the center) to minimize rubber particle contamination.
5. Direct solvent slowly down the inner wall of the vial — do not spray directly onto the lyophilized cake.
6. Gently roll the vial between your palms for 30–60 seconds. Do not invert repeatedly or shake.
7. Allow to stand at room temperature for 5–10 minutes. Gently roll once more if pellet remains.
8. Visually inspect: the solution should be clear to slightly opalescent. Cloudiness, particulates, or color indicates protein aggregation.
Reconstitution Volume Reference
| Vial Size | Target Concentration | Reconstitution Volume |
|---|---|---|
| 100 mcg | 100 mcg/mL (100 ng/µL) | 1.0 mL BAC water or PBS+BSA |
| 100 mcg | 200 mcg/mL (200 ng/µL) | 0.5 mL BAC water or PBS+BSA |
| 1 mg | 1 mg/mL | 1.0 mL PBS + 0.1% BSA |
| 1 mg | 500 mcg/mL | 2.0 mL PBS + 0.1% BSA |
Recommended diluent:
- •For cell culture / in vitro: PBS + 0.1% BSA (BSA prevents adsorption to labware surfaces and stabilizes the protein)
- •For in vivo SC/IM administration in animal models: Bacteriostatic water or sterile PBS (BSA may complicate pharmacokinetic measurements in serum; consult your IACUC protocol)
---
Storage and Stability
Follistatin-344's glycoprotein structure makes it substantially more labile than most synthetic research peptides. The half-life of biological activity at room temperature is measured in hours, not days.
| State | Temperature | Stability |
|---|---|---|
| Lyophilized (sealed) | -20°C | 12–24 months |
| Lyophilized (sealed) | 4°C | 6 months (avoid repeated temperature cycling) |
| Reconstituted | 4°C | 7–14 days (use within 7 days for optimal activity) |
| Reconstituted (aliquoted) | -20°C | 3–6 months (single freeze-thaw per aliquot) |
| Reconstituted | Room temperature | < 4 hours (discard) |
Aliquoting strategy: After reconstitution, immediately divide the solution into single-experiment aliquots (e.g., 50–100 µL each) in low-binding tubes. Snap-freeze in liquid nitrogen or dry ice, then transfer to -20°C. This eliminates repeated freeze-thaw degradation.
---
Research Dosage Protocols: Preclinical Models
The dosage ranges below are compiled from peer-reviewed preclinical studies. All parameters describe animal model research and are not applicable to human use.
Rodent Dosing Parameters
| Research Model | Dose Range | Frequency | Route | Study Context |
|---|---|---|---|---|
| Wild-type mice (hypertrophy) | 50–100 mcg/kg | Every other day (EOD) | SC | Muscle mass endpoints (Lee et al.) |
| mdx mice (DMD model) | 100–200 mcg/kg | Daily | IM or SC | Dystrophy reversal (Rodino-Klapac et al., 2007) |
| Aged rodents (sarcopenia) | 100–150 mcg/kg | 3× per week | SC | Sarcopenia / NMJ restoration studies |
| Ovariectomized rodents | 50–100 mcg/kg | EOD | SC | Bone/muscle dual endpoint models |
| In vitro / cell culture | 10–200 ng/mL | Continuous | Media | Receptor binding, satellite cell assays |
Non-Human Primate Parameters
| Parameter | Range | Notes |
|---|---|---|
| Dose | 20–50 mcg/kg | Lower than rodent; allometric scaling applies |
| Frequency | 2–3× per week | PK studies showed accumulation at daily dosing |
| Route | IV or SC | IV for PK characterization; SC for efficacy studies |
| Duration | 4–12 weeks | Most primate muscle mass studies |
Key Dosage Considerations
Serum half-life and dosing interval: Recombinant FS-344/315 has a short serum half-life in rodent models — approximately 1–4 hours — which necessitates frequent dosing when sustained myostatin suppression is required. In studies measuring cumulative hypertrophy over 4–8 weeks rather than acute receptor occupancy, some protocols use every-third-day or twice-weekly dosing, accepting intermittent trough periods.
Gene therapy vs. recombinant protein — critical distinction: The landmark follistatin studies by Mendell, Rodino-Klapac, and colleagues used AAV1-FS344 gene therapy, not recombinant protein. A single AAV injection achieves sustained, transgenic-level expression for months — a completely different pharmacology from repeat-dose recombinant protein. Do not extrapolate gene therapy dose equivalents to recombinant protein protocols.
Weight-based scaling: All in vivo follistatin dosing is weight-normalized (mcg/kg). Direct translation between species without allometric scaling is invalid. A 100 mcg/kg mouse dose does not correspond to the same biological exposure in a rat, primate, or any other species.
---
Administration Routes and Injection Site Guidance
Subcutaneous (SC)
Subcutaneous injection is the most common route in rodent muscle hypertrophy models. FS-315's low HSPG affinity allows it to distribute from the subcutaneous depot into systemic circulation, reaching skeletal muscle targets with reasonable efficiency.
Research guidance:
- •Rotate injection sites (dorsal neck scruff, flank) to minimize local tissue reactions
- •Injection volume: ≤ 10 mL/kg body weight in rodents (e.g., ≤ 0.2 mL for a 20g mouse)
- •Room-temperature injection is better tolerated than cold-solution administration
Intramuscular (IM)
IM injection is used in dystrophy models when local muscle-targeted delivery is preferred or when gene therapy protocols use direct intramuscular delivery. The Mendell BMD trial injected AAV1-FS344 directly into the extensor digitorum brevis.
For recombinant protein IM delivery:
- •Target the quadriceps, tibialis anterior, or gastrocnemius in rodent models
- •Volume: ≤ 50 µL per site in mice; ≤ 200 µL per site in rats
- •Minimize needle bore size (27–30 gauge) to reduce muscle trauma from repeated injections
Intravenous (IV)
IV delivery is primarily used in pharmacokinetic characterization studies in larger animal models. It is uncommon for standard muscle hypertrophy research due to the complexity of rodent tail vein access and the protein's short half-life, which would require continuous infusion for sustained receptor occupancy.
---
Myostatin Inhibition Timeline: What Research Models Show
Researchers designing study timelines should calibrate expectations based on the endpoint type:
| Endpoint | Earliest Signal | Peak Response | Study Duration |
|---|---|---|---|
| Myostatin serum neutralization | Hours to 24h | Dose-dependent | Duration of dosing |
| Smad2/3 phosphorylation reduction | 24–72h | 3–5 days | During active dosing |
| Satellite cell activation markers | 3–7 days | 7–14 days | First 2 weeks |
| Muscle fiber CSA increase | 2–3 weeks | 4–8 weeks | 6–12 weeks typical |
| Functional strength improvement | 4–6 weeks | 8–16 weeks | Longer protocols |
| Fibrosis reduction (DMD models) | 4–6 weeks | 8–12 weeks | Requires sustained dosing |
Satellite cell activation: One underappreciated aspect of follistatin's mechanism is its direct activation of muscle satellite cells (muscle stem cells) through a pathway independent of myostatin/activin receptor antagonism. Research by Gilson et al. (2009) demonstrated that follistatin promotes satellite cell proliferation as a parallel anabolic mechanism. Studies measuring regenerative endpoints should account for this by including satellite cell markers (Pax7, MyoD) in their assay panels alongside fiber CSA measurements.
---
Follistatin-344 vs. Follistatin-315: Sourcing and Protocol Relevance
When ordering from commercial research suppliers, products labeled "Follistatin-344" may contain either:
1. Full-length FS-344 precursor (344 amino acids; may undergo in-solution processing)
2. Mature FS-315 protein (the post-translationally processed circulating form with the C-terminal extension)
For most muscle biology applications, FS-315 is the functional form and the one characterized in most pharmacokinetic studies. Verify with your vendor which protein sequence and expression system they use. Differences in glycosylation (HEK293 vs. E. coli expression, for example) affect specific activity and in vivo half-life.
E. coli-expressed follistatin: Prokaryotic expression systems produce non-glycosylated follistatin. While suitable for some biochemical binding assays, non-glycosylated FS-344 has altered stability, reduced in vivo half-life, and may not recapitulate the pharmacology of the native glycoprotein. For in vivo animal model work, mammalian cell-expressed (HEK293 or CHO) recombinant protein is preferred.
---
Reconstitution Tools Reference
For researchers new to protein reconstitution, our peptide reconstitution calculator supports concentration calculation, volume planning, and dose preparation across common research vial sizes.
For protocol context on related research compounds that target overlapping muscle biology pathways, see:
- •BPC-157 Dosage Protocol Guide
- •TB-500 Dosage Protocol Guide
- •Follistatin-344 Research Profile — Mechanism & Multi-Tissue Biology
---
Storage and Handling Checklist
Before initiating a follistatin-344 research protocol, confirm the following:
- •[ ] Lyophilized stock stored at -20°C in a non-frost-free freezer (frost-free cycles cause repeated temperature fluctuations)
- •[ ] Reconstitution buffer prepared (sterile PBS + 0.1% BSA for cell culture; BAC water for in vivo)
- •[ ] Single-use aliquots planned before first reconstitution
- •[ ] Low-binding microcentrifuge tubes sourced for aliquot storage
- •[ ] BSA carrier protein available (if using low-concentration working solutions < 100 ng/mL)
- •[ ] Protein activity assay or positive control included in experimental design
- •[ ] IACUC protocol covers follistatin dosing route, volume, and frequency for the planned study
---
Research Use Only Disclaimer
Follistatin-344 recombinant protein is classified as a Research Use Only (RUO) reagent. It is not approved by the FDA, EMA, or any other regulatory body for diagnostic or therapeutic use in humans or animals. The dosage parameters, reconstitution protocols, and administration guidance in this article are derived from peer-reviewed preclinical research literature and are provided for scientific educational purposes only.
Researchers working with follistatin-344 should comply with applicable institutional biosafety guidelines, obtain required IACUC approvals for animal studies, and follow their institution's regulations for recombinant protein handling and disposal.
---
For the complete mechanistic background, isoform biology, gene therapy research history, and multi-tissue applications of follistatin-344, see our companion research profile article.